EGFR and gastric cancer: However, EPHA2, which is participates in crosstalk with other membrane receptors and impinged on downstream RAS/PI3K/AKT and RAS/MAPK signaling pathways, might be involved in the mechanism of acquired resistance to EGFR inhbitors in treating GC [12].